Sarah James Hill
Affiliations: | 2014 | Biology: Medical Sciences | Harvard University, Cambridge, MA, United States |
Website:
https://www.dana-farber.org/find-a-doctor/sarah-j-hill/Google:
"Sarah J Hill"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| David M. Livingston | grad student | 2014 | Harvard | |
| (New insights into BRCA1 function and its role in cancer development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yang Z, Mogre S, He R, et al. (2024) The ORFIUS complex regulates ORC2 localization at replication origins. Nar Cancer. 6: zcae003 |
| Wan C, Keany MP, Dong H, et al. (2020) Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer. Cancer Research |
| Bouberhan S, Philp L, Hill S, et al. (2020) Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers. 12 |
| Hill SJ, Lizotte P, Kesten N, et al. (2020) Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction Clinical Cancer Research. 26 |
| Konstantinopoulos PA, Luo W, Liu JF, et al. (2019) Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901021 |
| Hill SJ, Decker B, Roberts EA, et al. (2019) Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS Clinical Cancer Research. 25 |
| Hill SJ, Lizotte P, Horowitz NS, et al. (2019) Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids Cancer Research. 79 |
| Do KT, Hill SJ, Kochupurakkal B, et al. (2019) Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors Cancer Research. 79 |
| Hill SJ, Decker B, Roberts EA, et al. (2018) Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery |
| Aref AR, Campisi M, Ivanova E, et al. (2018) 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab On a Chip |